Rhythm Pharmaceuticals Files 8-K
Ticker: RYTM · Form: 8-K · Filed: Jul 10, 2024 · CIK: 1649904
| Field | Detail |
|---|---|
| Company | Rhythm Pharmaceuticals, Inc. (RYTM) |
| Form Type | 8-K |
| Filed Date | Jul 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $150,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
Rhythm Pharma filed an 8-K, check for updates.
AI Summary
Rhythm Pharmaceuticals, Inc. filed an 8-K on July 10, 2024, to report other events and financial statements/exhibits. The filing does not detail specific transactions or financial results but serves as a notification of these items being filed.
Why It Matters
This filing indicates Rhythm Pharmaceuticals is making official disclosures to the SEC, which could include important operational updates or financial information that investors should review.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain specific negative or positive news, making the immediate risk level low.
Key Players & Entities
- Rhythm Pharmaceuticals, Inc. (company) — Registrant
- July 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38223 (company_id) — Commission File Number
- 46-2159271 (company_id) — IRS Employer Identification Number
- 222 Berkeley Street 12th Floor Boston, MA 02116 (address) — Principal executive offices
- ( 857 ) 264-4280 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported by Rhythm Pharmaceuticals?
The filing does not specify the 'Other Events' in the provided text, only that this item is being reported.
What is the significance of filing 'Financial Statements and Exhibits' on an 8-K?
This indicates that Rhythm Pharmaceuticals is officially submitting financial statements and/or exhibits to the SEC, which may contain material information for investors.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on July 10, 2024.
What is Rhythm Pharmaceuticals' principal executive office address?
The principal executive offices are located at 222 Berkeley Street, 12th Floor, Boston, MA 02116.
Is there any information about former company names or addresses?
The filing notes a former company name of 'RHYTHM METABOLIC, INC.' with a date of name change on August 3, 2015, but no former address is listed as changed.
Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-07-10 16:07:18
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share RYTM The Nasdaq
- $150,000,000 — are, for an aggregate purchase price of $150,000,000 on April 15, 2024. A copy of the legal
Filing Documents
- tm2418975d2_8k.htm (8-K) — 24KB
- tm2418975d2_ex5-1.htm (EX-5.1) — 14KB
- tm2418975d2_ex5-1img001.jpg (GRAPHIC) — 10KB
- tm2418975d2_ex5-1img002.jpg (GRAPHIC) — 6KB
- 0001104659-24-078941.txt ( ) — 233KB
- rytm-20240710.xsd (EX-101.SCH) — 3KB
- rytm-20240710_lab.xml (EX-101.LAB) — 33KB
- rytm-20240710_pre.xml (EX-101.PRE) — 22KB
- tm2418975d2_8k_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Latham & Watkins LLP. 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1). 104 Cover page interactive data file (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RHYTHM PHARMACEUTICALS, INC. Date: July 10, 2024 By: /s/ Hunter Smith Hunter Smith Chief Financial Officer